ANRO

Insider Trades

Name	Value	Action	Price	Current Price
Savitz AdamCHIEF MEDICAL OFFICER $134k10.7k shares BuyJul 9, 2024 $12.53 --
Savitz AdamCHIEF MEDICAL OFFICER $18k1.4k shares BuyJul 9, 2024 $13.15 --
Savitz AdamCHIEF MEDICAL OFFICER $39k2.9k shares BuyJul 10, 2024 $13.22 --

News

businesswire.comAlto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedoniabusinesswire.comJun 15

gurufocus.comAlto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directorsgurufocus.comMay 28

businesswire.comAlto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directorsbusinesswire.comMay 28

businesswire.comAlto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Awardbusinesswire.comMay 15

businesswire.comAlto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlightsbusinesswire.comMay 13

Trade ANRO

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.

CEO: Amit Etkin
IPO Date: Feb 2, 2024

Market Data

Open: $22.50
High: $23.26
Low: $21.76
Volume: 194.6K
Avg Volume: 336.7K
52W High: $28.44
52W Low: $2.15

Valuation

Market Cap: $798M
Enterprise Value: $540M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-52M
Revenue: $0
Net Income: $-63M
Cash: $176M
Debt: $4.4M

Events

EarningsAug 12

EPS est. -0.71